Smith & Nephew plc Share Price and Company Fundamentals
Last traded: Today at 2:44 PM
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Key Metrics
PE ratio
23.13
PB ratio
268.56
Dividend yield
2.33%
Beta
0.68
Market cap
£10.60B
Enterprise value
£13.49B
Company profile
| Industry / Sector | Medical Devices / Healthcare |
|---|---|
| Full time employees | 17000 |
| Website | https://www.smith-nephew.com |
| Mailing address | Building 5 Croxley Park Hatters Lane Watford WD18 8YE United Kingdom |
| Phone / Fax | 44 1923 477 100 / |
Dividends
Dividend yield
2.33%
Dividend amount
£0.29
Payout ratio
52.72%
5Y Avg. yield
-%
Smith & Nephew plc paid £0.29 dividend and the ex-dividend date was 26 Mar 2026.The dividend payout ratio is 52.72%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.SN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Mar 2026, following are the company executives and directors listed on Smith & Nephew plc.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Deepak S. Nath Ph.D. | CEO & Director | 53 | |
| Mr. John Terence Rogers | CFO & Executive Director | 56 | |
| Mr. Paul Connolly | President of Global Operations | 57 | |
| Emily Heaven | Head of Investor Relations | ||
| Ms. Helen Barraclough | Group General Counsel & Company Secretary | 46 | |
| Ms. Alison Parkes | Chief Compliance Officer & Compliance APAC | 53 | |
| Mr. Charles Reynolds | Head of Corporate Communication | ||
| Dr. Ajay Dhankhar Ph.D. | Chief Corporate Development & Strategy Officer | 54 | |
| Ms. Elga Lohler | Chief Human Resources Officer | 57 | |
| Dr. Vasant Padmanabhan Ph.D. | President Research & Development, ENT and Emerging Markets | 58 |
Profitability and management effectiveness
Profit margin
10.14%
Operating margin
11.40%
Return on assets
4.77%
Return on equity
11.84%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Smith & Nephew plc is 10.60B and its enterprise value is 13.49B. The enterprise value to revenue ratio of SN is 2.19. The enterprise value to EBITDA ratio of SN is 9.87.
The SN's stocks Beta value is 0.68 making it 32% less volatile compared to LSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Smith & Nephew plc (LSE:SN) Frequently Asked Questions
1. What is Smith & Nephew plc's Stock Symbol?
Smith & Nephew plc trades on LSE under the ticker symbol "SN".
2. What is Smith & Nephew plc's stock price today?
One share of SN stock can currently be purchased for approximately £1249.
3. How can I contact Smith & Nephew plc?
Smith & Nephew plc's mailing address is Building 5 Croxley Park Hatters Lane Watford WD18 8YE United Kingdom. The company can be reached via phone at 44 1923 477 100.
4. What is Smith & Nephew plc's official website?
The official website of Smith & Nephew plc is https://www.smith-nephew.com.